Core Concepts
Specific scleroderma autoantibodies can predict cancer risk in patients.
Abstract
TOPLINE:
Five scleroderma immune responses linked to cancer risk.
METHODOLOGY:
Study included patients from Johns Hopkins and University of Pittsburgh.
676 scleroderma patients with cancer history compared to 687 controls.
Serum tested for various scleroderma autoantibodies.
Examined association between autoantibodies and cancer risk.
TAKEAWAYS:
Anti-POLR3 and anti-Ro52 linked to increased cancer risk.
Anti-centromere and anti-U1RNP linked to decreased cancer risk.
Associations held for cancer-associated scleroderma.
Patients with specific combinations of autoantibodies had varied cancer risk.
IN PRACTICE:
Study not yet applicable in practice.
SOURCE:
Study led by Ji Soo Kim, PhD, at John Hopkins University.
DISCLOSURES:
Study supported by various foundations and institutes.
Stats
A total of 676 patients with scleroderma and a history of cancer were compared with 687 control patients with scleroderma but without a history of cancer.
Anti-POLR3 and monospecific anti-Ro52 were associated with significantly increased overall cancer risk.
Anti-centromere and anti-U1RNP were associated with a decreased cancer risk.
Patients positive for anti-Ro52 in combination with either anti-U1RNP or anti-Th/To had a decreased risk of cancer.
Quotes
"Anti-POLR3 and monospecific anti-Ro52 were associated with significantly increased overall cancer risk."
"Patients positive for anti-Ro52 in combination with either anti-U1RNP or anti-Th/To had a decreased risk of cancer."